Abstract: The use of L-lysine in a composition and method for the prophylaxis and treatment of telogen effluvium is provided. A kit is also provided which includes a plurality of separate containers each containing at least one active agent useful in a combination therapy for said method.

Abstract: Drug and multidrug resistant modulators of the formula: ##STR1## where R.sup.1 and R.sup.2 are independently hydrogen or halo; A is --CH.sub.2 --CH.sub.2 --, --CH.sub.2 --CHR.sup.4 --CH.sub.2 --, or --CH.sub.2 --CHR.sup.5 --CHR.sup.6 --CH.sub.2 --, where R.sup.4 is --H, --OH, or acyloxy; one of R.sup.5 or R.sup.6 is --H, --OH, or acyloxy, and the other is --H; R.sup.3 is a polyaryl; and pharmaceutically acceptable salts and solvates thereof, are described and claimed. Use of the new compounds in the preparation of pharmaceutical compositions is described and claimed. In addition, methods for treating drug and multidrug resistance in various diseases using a compound, or pharmaceutically acceptable salt or solvate thereof, of this invention are described and claimed. Also, methods of enhancing oral bioavailability of a drug and methods of enhancing bioavailability of a drug to the brain using a compound, or pharmaceutically acceptable salt or solvate thereof, of this invention are described and claimed.

Abstract: This invention relates to a cosmetic composition having a UV blocking action in a wide region from UVB to UVA and capable of preventing erythema and melanism due to burning by the sun.The conventional fine particles of titanium dioxide are insufficient in the effect for blocking ultraviolet ray and, furthermore, the feeling to the skin becomes poorer, and the finish becomes powdery.This invention resides in the formulation, into a cosmetic composition, of spindle shaped fine particles of titanium dioxide having an average short diameter of 0.03 to 0.06 .mu.m, an average long diameter of 0.08 to 0.12 .mu.m, and an aspect ratio (long diameter/short diameter) of 2 to 4 or the spindle shaped fine particles and a metal oxide having an average particle size of 0.2 .mu.m or more.

Abstract: Mammalian hair growth is reduced by applying to the skin an inhibitor of protein-tyrosine kinase.

Abstract: A method for treatment of prophylaxis of skin against ageing, against inflammation and for protection from photoreaction and oxidative influences which comprise applying a formulation comprising alpha-glucosyl rutin and one or more cinnamic acid derivatives to the skin.

Abstract: Dermatological/cosmetic compositions for reducing or decelerating human hair loss comprise an effective hair loss-reducing amount of combinatory immixture of (a) at least one antifungal agent and (b) at least one halogenated antibacterial agent other than a macrolide or pyranoside, characteristically formulated in a topically physiologically acceptable medium therefor.

Abstract: Edible oil containing arachidonic acid obtained from microorganisms belonging to the subgenus Mortierella of the genus Mortierella and being capable of producing arachidonic acid are provided. The oil contain little unsaponifiable matters and, above all, the smallest possible amount of sterol with cyclopropane structure which have not been recognized as food components, and are suitable for the production of foods, in particular, infant formula.Arachidonic acid-containing edible oil originating in microorganisms containing not more than 0.8% by weight, preferably not more than 0.6% by weight of unsaponifiable matters and 20% by weight or more of arachidonic acid. Further, these edible oil contain not more than 0.3% by weight, preferably not more than 0.15% by weight of 24,25-methylenecholest-5-en-3 .beta.-ol. The microorganisms are those belonging to the subgenus Mortierella of the genus Mortierella and being capable of producing arachidonic acid.

Abstract: Method and composition for treating painful conditions of the anorectal region. The compositions include a combination of an .alpha.-adrenergic blocker and sucralfate, a combination of .alpha.-adrenergic blocker and lidocaine, and a combination of an .alpha.-adrenergic blocker, lidocaine, and sucralfate. Alternatively, the composition may contain only an .alpha.-adrenergic blocker. Additional active ingredients for reduction of anal pain may be added to the composition, particularly capsaicin. The compositions may be included in a petrolatum base along with a water soluble lubricant. These compositions have been found effective in treating painful conditions in the anal region, such as anal fissures, inflamed or recently thrombosed hemorrhoids, and chronic anal pain.

Abstract: The therapeutic use of basic amino acids, acylated basic amino acids and their pharmacologically acceptable salts is disclosed for the treatment of a cellular disorder in a mammal which is induced by elevated levels of ceramide.

Abstract: The present invention provides a method for increasing the aerobic capacity of muscle of an animal, the method comprising administering a dose of HMB to the animal such that the aerobic capacity is increased without a substantial increase in the mass of the muscle. The present invention also provides a method for increasing the amount of hemoglobin in the blood of an animal having muscles, the method comprising administering a dose of HMB to the animal such that the amount of hemoglobin in the animal is increased without a substantial increase in the mass of the muscles.

Abstract: Formulations of intravenous anesthetic propofol emulsions are provided which contain sufficiently low concentrations of soybean oil to produce a stable emulsion and simultaneously provide reduced nutrients, which inhibit microbial growth thereby providing protection against accidental microbial contamination during long-term IV infusions. In addition to the inhibition of microbial growth due to a reduction of nutrients, the formulation exhibits unanticipated additional microbial inhibition due to an increased availability of propofol. The low concentration of soybean oil also provides a formulation that reduces the chances of fat overload when administered over an extended period of time to chronically ill patients.

Abstract: A method of treating male erectile dysfunction comprising administering to a male human a pyrimidine compound of formula I.

Abstract: A method for preventing and treating headache pain comprising administering a tricyclic antidepressant compound locally to the nasal mucosa to a patient suffering from headaches.

Abstract: This invention relates to the treatment of essential hypertension by administration of anti-hypertensive effective amounts of 4-hydroxy-2,2,6,6-tetramethyl-1-piperidine-1-oxyl (tempol).

Abstract: This invention discloses a method of using an aldosterone antagonist such as spironolactone, at a dosage which does not disrupt a patient's normal electrolyte and water-retention balance, to inhibit myocardial fibrosis, including left ventricular hypertrophy (LVH).

Abstract: Novel antiandrogenic agents are provided. An exemplary group of compounds has the structural formula (I) ##STR1## wherein R.sup.1 through R.sup.10, a and b are as defined herein. Pharmaceutical compositions and methods for using the compounds of formula (I) to treat androgen-related clinical conditions are provided, as are methods and compositions for using the compounds as contraceptive agents.

Abstract: The present invention relates to a method of inhibiting N-methyl-D-aspartate (NMDA) glutamate receptor-mediated ion channel activity (NMDA receptor activity), comprising contacting a neuronal cell (e.g., hippocampal neuron, spinal cord cell) with an effective amount (e.g., 1 to 500 .mu.M) of a derivative of pregnenolone sulfate. Derivatives of pregnenolone sulfate that inhibit NMDA receptor activity include pregnenolone sulfate derivatives in which the A ring includes at least one double bond; PS in which the A ring is fully unsaturated; PS derivatives in which the double bond at the C5-C6 position is reduced; and PS in which the moiety at the C3, C5, C6, C7, C11, C17, C20 and/or C21 position is modified. It further relates to PS derivatives which have modifications at other positions (e.g., C10, C10, C13, C18, C19), alone or in combination, and are inhibitors of NMDA receptor activity. The present invention also relates to a method of modulating or altering (e.g.

Abstract: Animal food formulations, preferably dry cat foods and treats, or medicaments, e.g., tablets, gels or suppositories, that contain an amount of an enzyme (bromelain) effective to treat and/or prevent hairballs are provided. These formulations can be ingested chronically, i.e., daily, with no adverse effects.

Abstract: The present invention relates to a method of treating a patient with a fibrotic or fibroproliferative disorder and a method of suppressing formation of collagen and collagen-like substances or biosynthesis of procollagen in living systems by administering to a patient or living system, respectively, an effective amount of a compound of Formulae (I) or (II) and derivatives thereof: ##STR1## R.sub.1, R.sub.2, R.sub.3, and R.sub.4 each individually represent a hydrogen, an alkyl, alkenyl, or alkoxy group containing 1 to about 8 carbon atoms, an aryl, aralkyl, or cycloalkyl group containing about 5 to 12 carbon atoms, or a carboalkoxy or carbamyl group containing up to 8 carbon atoms, or a peptide or peptidomimetic moiety containing 10 to about 30 carbon atoms.

Abstract: Seborrheic dermatitis of the scalp is treated by a synergistic combination of a cytotoxic agent and an antifungal agent.